KLF4 defines the efficacy of the epidermal growth factor receptor inhibitor, erlotinib, in triple-negative breast cancer cells by repressing the EGFR gene

por Roberts, Melyssa S., Anstine, Lindsey J., Finke, Viviane S., Bryson, Benjamin L., Webb, Bryan M., Weber-Bonk, Kristen L., Seachrist, Darcie D., Majmudar, Parth R., Keri, Ruth A.
Publicado 2020